A Phase 3 interventional study of Epoetin Hospira and Epogen Amgen in Chronic Renal Failure and Chronic Kidney Disease, sponsored by Pfizer. Completed at 73 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-08-09.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing Epoetin Alfa in Kidney Failure, Chronic — none open to participants now, none under way, none of them phase 3. Epoetin Alfa · Kidney Failure, Chronic.
Among the 13 studies testing Epoetin Alfa in Kidney Failure, Chronic, this one is the 6th largest by enrollment, is one of 5 that started in 2012, is one of 5 in phase 3, and was the 9th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →None of the 13 studies testing Epoetin Alfa in Kidney Failure, Chronic is open now. The open studies under Kidney Failure, Chronic, anywhere →
Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 5 started in 2012.
This study's enrollment of 320 is above the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 292 across the 13 interventional studies. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 13 have an industry lead sponsor. The 7 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
10 studies in Kidney Failure, Chronic by Pfizer: none open now, none under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 10 studies in Kidney Failure, Chronic by Pfizer, this one is the 4th largest by enrollment, is one of 4 that started in 2012, is one of 5 in phase 3, and was the 4th registered.
Pfizer’s Kidney Failure, Chronic studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing Epoetin Alfa in Kidney Failure, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 10 in Kidney Failure, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate therapeutic equivalence of subcutaneous (SC) Epoetin Hospira compared to SC Epogen (Amgen), based on maintenance of hemoglobin (Hb) levels and study drug dose requirements in patients treated for anemia associated with chronic renal failure and on hemodialysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Hemodialysis patients with chronic renal failure and renal anemia currently on stable Epogen (Amgen) dose administered IV or SC, 1 to 3 times per week for whom the following apply:
If female, patient must be for at least one year prior to randomization, surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or practicing at least one of the following methods of :
If hormonal contraceptives are used, the specific contraceptive must have been used for at least 3 months prior to randomization. If the patient is currently using a hormonal contraceptive, she should also use a barrier method during this study and for at least 30 days following the administration of the patient's last dose
Exclusion Criteria:
Any of the following within 3 months prior to randomization:
History of any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Epoetin Hospira
Biological: Epoetin Hospira
Epogen (Amgen)
Biological: Epogen Amgen
Variable dose
Variable dose
Also known as: Epoetin Alfa
Mean Weekly Hemoglobin Level From Week 30 to Week 34: Maintenance Period
Time frame: Week 30 up to Week 34
Mean Weekly Dosage of Study Medication From Week 30 to Week 34: Maintenance Period
Time frame: Week 30 up to Week 34
Mean Weekly Hemoglobin Level From Week 19 to Week 34: Maintenance Period
Time frame: Week 19 up to Week 34
Mean Weekly Dosage of Study Medication From Week 19 to Week 34: Maintenance Period
Time frame: Week 19 up to Week 34
Total Dose of Study Medication Administered: Maintenance Period
In this outcome measure mean of total dose of study medication administered in maintenance period was reported.
Time frame: Week 19 up to Week 34
Percentage of Participants With Mean Weekly Hemoglobin Level Within the Target Range: Maintenance Period
Percentage of participants who had hemoglobin level within the target range of 9 to 11 g/dL for the specified weeks were reported.
Time frame: Week 26, 34
Percentage of Participants Who Required Permanent Dose Changes: Maintenance Period
Time frame: Week 19 up to Week 34
Percentage of Participants Who Required Temporary Dose Changes: Maintenance Period
Time frame: Week 19 up to Week 34
Percentage of Participants With Any Transient Change of Hemoglobin Level Greater Than (>) 1.0 Gram Per Deciliter (g/dL): Maintenance Period
Time frame: Week 19 up to Week 34
Percentage of Participants With Mean Weekly Hemoglobin Level Outside the Target Range: Maintenance Period
Percentage of participants who had hemoglobin level outside the target range of 9 to 11 g/dL for the specified weeks were reported.
Time frame: Week 26, 34
Percentage of Participants Who Qualified as Optimally Titrated and Stable: Titration Period
Time frame: Week 1 up to Week 18
Percentage of Participants Who Received Blood Transfusions: Maintenance Period
Time frame: Week 19 up to Week 34
Number of Participants With Change in Mean Dose of Study Medication Based on Hemoglobin Level: Maintenance Period
In this outcome measure number of participants with change (increase and decrease) in mean dose of Epoetin Hospira and Epogen were categorized and reported according to their mean hemoglobin levels. Hemoglobin levels were divided in following classes: \>11.0 g/dL, from 9.0 to 11.0 g/dL and \<9.0 g/dL
Time frame: Week 19 up to Week 34
Percentage of Participants With Any Transient Change of Hemoglobin Level Greater Than (>) 2.0 Gram Per Deciliter (g/dL) in Hemoglobin Level: Maintenance Period
Time frame: Week 19 up to Week 34
Percentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL): Maintenance Period
Time frame: Week 19 up to Week 34
Percentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL): Maintenance Period
Time frame: Week 19 up to Week 34
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events.
Time frame: Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38
Number of Participants With Treatment-Emergent Adverse Events by Severity
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. An AE was assessed according to severity; mild (AE was transient and easily tolerated by the participant), moderate (caused problem that did not interfere significantly with usual activities) and severe (caused problem that interferes significantly with usual activities and might be incapacitating or life-threatening).
Time frame: Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38
Number of Participants With Treatment Related Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant who received study drug.
Time frame: Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38
Number of Participants That Discontinued Treatment Due to a Treatment Emergent Adverse Event
In this outcome measure number of participants discontinued from study drug (Epoetin Hospira, Epogen) due to any AE were reported.
Time frame: Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38
Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters
Laboratory parameters: Hematology (hematocrit, hemoglobin, red blood cell count, reticulocytes, white blood cell count, neutrophils, bands, lymphocytes, monocytes, basophils, eosinophils, platelet count, mean corpuscular volume); coagulation panel (prothrombin time, international normalized ratio, activated partial thromboplastin time); clinical chemistry (blood urea nitrogen, creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, gamma-glutamyl transpeptidase, alkaline phosphatase, sodium, potassium, calcium, magnesium, phosphorus, uric acid, total protein, glucose, albumin, C-reactive protein, plasma ferritin, transferrin saturation). Participants with clinically significant change from baseline in laboratory parameters were as determined by the investigator.
Time frame: Titration Period: Baseline (Pre-dose on Week 1) up to Week 18 and Maintenance Period: Baseline (Pre-dose on Week 19) up to Week 38
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
Vital sign parameters: temperature (oral, tympanic, or other), blood pressure (diastolic and systolic), heart rate (in a seated position) and dry weight (post-dialysis). Participants with clinically significant change from baseline in vital signs were as determined by the investigator.
Time frame: Titration Period: Baseline (Pre-dose on Week 1) up to Week 18 and Maintenance Period: Baseline (Pre-dose on Week 19) up to Week 38
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)
ECG parameters: PR interval, QRS complex, QT interval and QTC interval. Participants with clinically significant change from baseline in ECG were as determined by the investigator.
Time frame: Titration Period: Baseline (Pre-dose on Week 1) up to Week 18 and Maintenance Period: Baseline (Pre-dose on Week 19) up to Week 38
Number of Participants With Clinically Significant Change From Baseline in Physical Examination
Physical examination included examination of the following: skin, eyes, ears, throat, cardiac, respiratory, gastrointestinal, genitourinary and musculoskeletal systems. Participants with clinically significant change from baseline in physical examination were as determined by the investigator.
Time frame: Titration Period: Baseline (Pre-dose on Week 1) up to Week 18 and Maintenance Period: Baseline (Pre-dose on Week 19) up to Week 38
Percentage of Participants With Anti-Recombinant Human Erythropoietin (Anti-rhEPO) Antibodies
Percentage of participants with presence of anti-rhEPO antibodies were reported in this outcome measure. Radioimmunoprecipitation assay method was used to determine the presence of anti-rhEPO antibodies.
Time frame: Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38
Percentage of Participants With General Tolerability
General tolerability was classified as: 1) excellent tolerability = no reaction, 2) good tolerability = minimal reaction, 3) mild intolerability = reaction above that normally observed with any kind of subcutaneous product, 4) moderate intolerability = marked reaction, but no need for discontinuation of treatment and 5) severe intolerability = treatment discontinued due to intolerability.
Time frame: Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38
Percentage of Participants With Local Tolerability
Local tolerability was classified as: 1) excellent tolerability = no reaction at site of injection, 2) good tolerability = minimal reaction at site of injection normally observed with any kind of subcutaneous product, 3) mild intolerability = reaction at site of injection above that normally observed with any kind of subcutaneous product, 4) moderate intolerability = marked reaction, but no need for discontinuation of treatment and 5) severe intolerability = treatment discontinued due to intolerability.
Time frame: Titration Period: Week 1 up to Week 18 and Maintenance Period: Week 19 up to Week 38
Participants with chronic renal failure were receiving Epoetin maintenance therapy prior to enrollment and treatment in this study.
| Milestone | Epoetin Hospira | Epogen |
|---|---|---|
| Started | 160 | 160 |
| Treated | 80 | 86 |
| Completed | 124 | 122 |
| Not completed | 36 | 38 |
| Withdrew: Adverse event | 4 | 6 |
| Withdrew: Did not meet criteria | 32 | 32 |
| Milestone | Epoetin Hospira | Epogen |
|---|---|---|
| Started | 124 | 122 |
| Completed | 106 | 105 |
| Not completed | 18 | 17 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Did not meet criteria | 0 | 2 |
| Withdrew: Kidney transplant | 3 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Withdrawal by subject | 4 | 6 |
| Withdrew: Site closure | 3 | 1 |
| Withdrew: Started peritoneal dialysis | 1 | 0 |
| Withdrew: Long term hospitalization | 0 | 1 |
| Withdrew: Sponsor's decision | 1 | 0 |
| Withdrew: Elevated hemoglobin | 1 | 0 |
| g/dL | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|
| Mean Weekly Hemoglobin Level From Week 30 to Week 34: Maintenance Period | 10.17 ± 0.821 | 10.11 ± 0.838 |
| unit per kilogram per week (U/kg/week) | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|
| Mean Weekly Dosage of Study Medication From Week 30 to Week 34: Maintenance Period | 82.07 ± 95.517 | 79.14 ± 82.264 |
| g/dL | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|
| Mean Weekly Hemoglobin Level From Week 19 to Week 34: Maintenance Period | 10.20 ± 0.625 | 10.22 ± 0.665 |
| U/kg/week | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|
| Mean Weekly Dosage of Study Medication From Week 19 to Week 34: Maintenance Period | 81.93 ± 93.824 | 75.08 ± 72.174 |
In this outcome measure mean of total dose of study medication administered in maintenance period was reported.
| units of study medication | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|
| Total Dose of Study Medication Administered: Maintenance Period | 102003.2 ± 135560.52 | 86478.5 ± 83351.03 |
Percentage of participants who had hemoglobin level within the target range of 9 to 11 g/dL for the specified weeks were reported.
| percentage of participants | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|
| Week 26 | 73.5 | 60.9 |
| Week 34 | 79.8 | 74.0 |
| percentage of participants | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|
| Percentage of Participants Who Required Permanent Dose Changes: Maintenance Period | 30.2 | 25.0 |
| percentage of participants | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|
| Percentage of Participants Who Required Temporary Dose Changes: Maintenance Period | 55.8 | 62.0 |
| percentage of participants | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|
| Percentage of Participants With Any Transient Change of Hemoglobin Level Greater Than (>) 1.0 Gram Per Deciliter (g/dL): Maintenance Period | 29.1 | 52.2 |
Percentage of participants who had hemoglobin level outside the target range of 9 to 11 g/dL for the specified weeks were reported.
| percentage of participants | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|
| Week 26 | 13.5 | 19.3 |
| Week 34 | 10.1 | 13.0 |
| percentage of participants | Epoetin Hospira: Titration Period | Epogen: Titration Period |
|---|---|---|
| Percentage of Participants Who Qualified as Optimally Titrated and Stable: Titration Period | 47.5 | 47.7 |
| percentage of participants | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|
| Percentage of Participants Who Received Blood Transfusions: Maintenance Period | 4.0 | 4.1 |
In this outcome measure number of participants with change (increase and decrease) in mean dose of Epoetin Hospira and Epogen were categorized and reported according to their mean hemoglobin levels. Hemoglobin levels were divided in following classes: \>11.0 g/dL, from 9.0 to 11.0 g/dL and \<9.0 g/dL
| Participants | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|
| Dose Decrease: Hb <9.0 g/dL | 9 | 10 |
| Dose Decrease: Hb (9.0 to 11.0 g/dL) | 20 | 14 |
| Dose Decrease: Hb >11.0 g/dL | 35 | 40 |
| Dose Increase: Hb <9.0 g/dL | 24 | 23 |
| Dose Increase: Hb (9.0 to 11.0 g/dL) | 11 | 3 |
| Dose Increase: Hb >11.0 g/dL | 7 | 13 |
| percentage of participants | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|
| Percentage of Participants With Any Transient Change of Hemoglobin Level Greater Than (>) 2.0 Gram Per Deciliter (g/dL) in Hemoglobin Level: Maintenance Period | 6.6 | 10.7 |
| percentage of participants | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|
| Percentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL): Maintenance Period | 4.1 | 9.0 |
| percentage of participants | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|
| Percentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL): Maintenance Period | 9.8 | 19.7 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events.
| Participants | Epoetin Hospira: Titration Period | Epogen: Titration Period | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|---|---|
| AEs | 45 | 54 | 85 | 86 |
| SAEs | 12 | 22 | 23 | 33 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. An AE was assessed according to severity; mild (AE was transient and easily tolerated by the participant), moderate (caused problem that did not interfere significantly with usual activities) and severe (caused problem that interferes significantly with usual activities and might be incapacitating or life-threatening).
| Participants | Epoetin Hospira: Titration Period | Epogen: Titration Period | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|---|---|
| Mild | 21 | 23 | 42 | 41 |
| Moderate | 15 | 16 | 24 | 27 |
| Severe | 9 | 15 | 19 | 18 |
An AE was any untoward medical occurrence in a participant who received study drug.
| Participants | Epoetin Hospira: Titration Period | Epogen: Titration Period | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|---|---|
| Number of Participants With Treatment Related Adverse Events (AEs) | 1 | 4 | 7 | 11 |
In this outcome measure number of participants discontinued from study drug (Epoetin Hospira, Epogen) due to any AE were reported.
| Participants | Epoetin Hospira: Titration Period | Epogen: Titration Period | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|---|---|
| Number of Participants That Discontinued Treatment Due to a Treatment Emergent Adverse Event | 4 | 6 | 4 | 4 |
Laboratory parameters: Hematology (hematocrit, hemoglobin, red blood cell count, reticulocytes, white blood cell count, neutrophils, bands, lymphocytes, monocytes, basophils, eosinophils, platelet count, mean corpuscular volume); coagulation panel (prothrombin time, international normalized ratio, activated partial thromboplastin time); clinical chemistry (blood urea nitrogen, creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, gamma-glutamyl transpeptidase, alkaline phosphatase, sodium, potassium, calcium, magnesium, phosphorus, uric acid, total protein, glucose, albumin, C-reactive protein, plasma ferritin, transferrin saturation). Participants with clinically significant change from baseline in laboratory parameters were as determined by the investigator.
| Participants | Epoetin Hospira: Titration Period | Epogen: Titration Period | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters | 0 | 0 | 0 | 0 |
Vital sign parameters: temperature (oral, tympanic, or other), blood pressure (diastolic and systolic), heart rate (in a seated position) and dry weight (post-dialysis). Participants with clinically significant change from baseline in vital signs were as determined by the investigator.
| Participants | Epoetin Hospira: Titration Period | Epogen: Titration Period | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Vital Signs | 0 | 0 | 0 | 0 |
ECG parameters: PR interval, QRS complex, QT interval and QTC interval. Participants with clinically significant change from baseline in ECG were as determined by the investigator.
| Participants | Epoetin Hospira: Titration Period | Epogen: Titration Period | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) | 0 | 0 | 0 | 0 |
Physical examination included examination of the following: skin, eyes, ears, throat, cardiac, respiratory, gastrointestinal, genitourinary and musculoskeletal systems. Participants with clinically significant change from baseline in physical examination were as determined by the investigator.
| Participants | Epoetin Hospira: Titration Period | Epogen: Titration Period | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Physical Examination | 0 | 0 | 0 | 0 |
Percentage of participants with presence of anti-rhEPO antibodies were reported in this outcome measure. Radioimmunoprecipitation assay method was used to determine the presence of anti-rhEPO antibodies.
| percentage of participants | Epoetin Hospira: Titration Period | Epogen: Titration Period | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|---|---|
| Percentage of Participants With Anti-Recombinant Human Erythropoietin (Anti-rhEPO) Antibodies | 0.0 | 0.0 | 0.0 | 0.0 |
General tolerability was classified as: 1) excellent tolerability = no reaction, 2) good tolerability = minimal reaction, 3) mild intolerability = reaction above that normally observed with any kind of subcutaneous product, 4) moderate intolerability = marked reaction, but no need for discontinuation of treatment and 5) severe intolerability = treatment discontinued due to intolerability.
| percentage of participants | Epoetin Hospira: Titration Period | Epogen: Titration Period | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|---|---|
| Excellent Tolerability | 68.8 | 67.4 | 63.9 | 50.8 |
| Good Tolerability | 28.8 | 25.6 | 27.0 | 27.9 |
| Mild Intolerability | 2.5 | 2.3 | 4.9 | 16.4 |
| Moderate Intolerability | 0.0 | 2.3 | 0.0 | 2.5 |
| Severe Intolerability | 0.0 | 0.0 | 1.6 | 1.6 |
Local tolerability was classified as: 1) excellent tolerability = no reaction at site of injection, 2) good tolerability = minimal reaction at site of injection normally observed with any kind of subcutaneous product, 3) mild intolerability = reaction at site of injection above that normally observed with any kind of subcutaneous product, 4) moderate intolerability = marked reaction, but no need for discontinuation of treatment and 5) severe intolerability = treatment discontinued due to intolerability.
| percentage of participants | Epoetin Hospira: Titration Period | Epogen: Titration Period | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|---|---|
| Excellent Tolerability | 70.0 | 66.3 | 67.2 | 54.1 |
| Good Tolerability | 25.0 | 25.6 | 24.6 | 30.3 |
| Mild Intolerability | 3.8 | 5.8 | 4.1 | 9.0 |
| Moderate Intolerability | 1.3 | 1.2 | 1.6 | 3.3 |
| Severe Intolerability | 0.0 | 0.0 | 0.0 | 2.5 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Epoetin Hospira: Titration Period | — | 12/80 (15%) | 16/80 (20%) |
| Epogen: Titration Period | — | 22/86 (25.6%) | 10/86 (11.6%) |
| Epoetin Hospira: Maintenance Period | — | 23/122 (18.9%) | 27/122 (22.1%) |
| Epogen: Maintenance Period | — | 33/122 (27%) | 24/122 (19.7%) |
| Event | Epoetin Hospira: Titration Period | Epogen: Titration Period | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 0/80 | 0/86 | 0/122 | 4/122 |
| SepsisInfections and infestations | 2/80 | 2/86 | 0/122 | 0/122 |
| Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/40 | 1/40 | 0/59 | 0/67 |
| Vulval CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/40 | 0/40 | 0/59 | 0/67 |
| Vulval Cancer Stage 0Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/40 | 1/40 | 0/59 | 0/67 |
| MenorrhagiaReproductive system and breast disorders | 0/40 | 1/40 | 0/59 | 0/67 |
| PneumoniaInfections and infestations | 1/80 | 1/86 | 3/122 | 2/122 |
| Acute Myocardial InfarctionCardiac disorders | 0/80 | 2/86 | 0/122 | 0/122 |
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 0/80 | 2/86 | 0/122 | 0/122 |
| Atrial FibrillationCardiac disorders | 0/80 | 1/86 | 1/122 | 2/122 |
| Event | Epoetin Hospira: Titration Period | Epogen: Titration Period | Epoetin Hospira: Maintenance Period | Epogen: Maintenance Period |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/80 | 0/86 | 10/122 | 8/122 |
| DizzinessNervous system disorders | 4/80 | 0/86 | 3/122 | 8/122 |
| FallInjury, poisoning and procedural complications | 0/80 | 0/86 | 8/122 | 3/122 |
| Injection Site PainGeneral disorders | 0/80 | 0/86 | 3/122 | 8/122 |
| PyrexiaGeneral disorders | 0/80 | 0/86 | 8/122 | 3/122 |
| Procedural HypotensionInjury, poisoning and procedural complications | 5/80 | 2/86 | 0/122 | 0/122 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 0/80 | 5/86 | 0/122 | 0/122 |
| HeadacheNervous system disorders | 4/80 | 4/86 | 0/122 | 0/122 |
| HyperkalaemiaMetabolism and nutrition disorders | 4/80 | 1/86 | 0/122 | 0/122 |
| Eosinophil Count IncreasedInvestigations | 4/80 | 0/86 | 0/122 | 0/122 |
Analysis population included all participants who were enrolled.
| Age, Categorical(Participants) | Epoetin Hospira | Epogen | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 109 | 117 | 226 |
| >=65 years | 51 | 43 | 94 |
| Sex: Female, Male(Participants) | Epoetin Hospira | Epogen | Total |
|---|---|---|---|
| Female | 77 | 84 | 161 |
| Male | 83 | 76 | 159 |
Ran from Jan 2012 to primary completion in Feb 2014, 25 months.
Results were first posted in Jun 2018, 4 years 3 months after primary completion. A results delay was requested in Feb 2015.
Of 42 industry-sponsored phase 3 interventional studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 40. This study's 25 months is below that.
Counting every sponsor, half of 66 studies reached it within 32 months; a quarter within 21 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epoetin Alfa